Cantor Fitzgerald analyst Charles Duncan raised the firm’s price target on Axsome Therapeutics to $96 from $88 and keeps an Overweight rating on the shares. Axsome reported Q3 revenue of $16.8M, which was in line estimates, Duncan tells investors in a research note. Axsome had a very productive quarter, highlighted by the approval of AUVELITY for MDD, and the analyst envisions AUVELITY becoming a mainstay.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXSM: